- Case report
- Open Access
- Open Peer Review
Familial tumoral calcinosis in two Chinese patients: a case series
© Zhang et al; licensee BioMed Central Ltd. 2011
- Received: 3 October 2010
- Accepted: 19 August 2011
- Published: 19 August 2011
Tumoral calcinosis is a rare and benign condition characterized by massive subcutaneous soft tissue deposits of calcium phosphate predominantly around large joints.
Familial tumoral calcinosis was present in two members of a Han Chinese family, namely, the son and daughter. The 14-year-old son had the first operation on his right sole of the foot at the age of six, and then experienced subsequent surgeries at a lesion in his right sole of the foot and left hip, respectively. The 16-year-old daughter underwent her first operation at the age of six in her left gluteal region, and subsequent surgeries were performed due to recurrence at the same lesion. Pathologic diagnoses of surgical specimens in both of the patients were reported as tumoral calcinosis. The laboratory results showed hyperphosphatemia with normal levels of serum calcium and alkaline phosphatase. Only surgical treatment was performed in both patients with satisfactory prognosis.
This is the first report of Chinese familial tumoral calcinosis. The etiopathogenisis and treatment are discussed.
- Calcium Phosphate
- Serum Phosphorus Level
- Tumoral Calcinosis
- Clear Edge
Tumoral calcinosis (TC) was first described by Inclan  in 1943 as slow growing, progressive masses usually found adjacent to large joints such as hips, shoulders and elbows. The masses are hard and painless. Recurrence tends to be observed at the same location subsequent to inadequate resection. Further identification is based on the pathogenesis. We describe the first two cases of familial TC in Chinese siblings, and present their clinical and pathological features.
A 16-year-old Han Chinese girl presented with a 10-year history of TC. Several resections had been performed due to recurrence. On physical examination, a large mass was found on her left hip and buttock. It was hard, fixed, nodular, and with a chalky effusion from fistula of involved skin. The motion of left hip articulation was intact. Her serum phosphorus level was higher than the upper normal range. Calcium and alkaline phosphatase were normal. Radiography revealed multilobular calcification near the left hip articulation and within the soft tissue of her buttock. The function of her skeleton and articulation nearby was normal. Pathological examination confirmed the diagnosis of TC. No similar complaint was made by other family members. The parents were first cousins.
TC is a rare disorder of mineral metabolism characterized by tumor-like periarticular deposition of calcium phosphate. There are two major clinical categories of TC based on its pathogenesis: familial tumoral calcinosis (FTC) with two subtypes: hyperphosphatemic FTC (HFTC) and normophosphatemic FTC (NFTC) based on serum phosphate status ; and secondary tumoral calcinosis. The diagnosis is confirmed mainly by medical history, physical examination, laboratory tests, radiological examination, and histology. The imaging features of FTC were explored by Jose et al. . Our two cases are consistent with the features of HFTC. HFTC is due to mutations in three genes: fibroblast growth factor-23 (FGF23) , coding for a potent phosphaturic protein; KL  encoding Klotho, serving as a co-receptor for FGF23; and GALNT3 , encoding a glycosyltransferase responsible for FGF23 O-glycosylation. Recently, FTC is considered a different manifestation (allelic variants) of the same disease as the hyperostosis-hyperphosphatemia syndrome (HHS), having similar biochemical abnormalities and caused by mutation of the GALNT3 gene . NFTC is characterized by the absence of metabolic abnormalities. It was found to be associated with the absence of functional SAMD9, a putative tumor suppressor and anti-inflammatory protein .
Resection of the mass is the preferred treatment for TC in a relatively stable stage in which the mass is capsulated, but recurrence is common. Phosphate depletion (aluminum hydroxide and acetazolamide) and low-phosphate, low-calcium diets, have a varied effect on FTC, but the benefits are limited . In our cases, only surgical treatment was performed considering the disadvantage of drug regimens on adolescents. Further study should be conducted to research the epidemiology and genomics of familial tumoral calcinosis in Asian families
In summary, our presentation is the first report regarding FTC in Chinese patients. Imaging and pathological examinations are the commonly used diagnostic procedures. Further study will focus on epidemiology in Asia, the mutations in genomics and the variance between Asian and Caucasian patients. Although the pathogenesis of the calcification process in TC is still controversial, surgical removal is the mainstay treatment with a satisfactory prognosis.
Written informed consent was obtained from the patients, with their parents' witness and consent, for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Inclan A, Leon P, Gomez CM: Tumoral Calcinosis. J Am Med Assoc. 1943, 121: 490-495.View ArticleGoogle Scholar
- Topaz O, Indelman M, Chefetz I, Geiger D, Metzker A, Altschuler Y, Choder M, Bercovich D, Uitto J, Bergman R, Richard G, Sprecher E: A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet. 2006, 79: 759-764. 10.1086/508069.View ArticlePubMedPubMed CentralGoogle Scholar
- Jean Jose DO, Fichter Braden, Paul Clifford: MD: Familial Tumoral Calcinosis. Am J Orthop. 2010, 39: E111-E113.PubMedGoogle Scholar
- Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005, 14: 385-390.View ArticlePubMedGoogle Scholar
- Ilana C, Eli S: Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochimica et Biophysica Acta. 2009, 1792: 847-852.View ArticleGoogle Scholar
- Specktor P, Cooper JG, Indelman M, Sprecher E: Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J Hum Genet. 2006, 51: 487-490. 10.1007/s10038-006-0377-6.View ArticlePubMedGoogle Scholar
- Joseph L, Hing SN, Presneau N, O'Donnell P, Diss T, Idowu BD, Joseph S, Flanagan AM, Delaney D: Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. Skeletal Radiol. 2010, 39: 63-68. 10.1007/s00256-009-0808-5.View ArticlePubMedGoogle Scholar
- Sprecher E: Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol. 2010, 130: 652-660. 10.1038/jid.2009.337.View ArticlePubMedGoogle Scholar
- Carmichael KD, Bynum JA, Evans E: Familial tumoral calcinosis: a fortyyear follow-up on one family. J Bone Joint Surg Am. 2009, 91: 664-671. 10.2106/JBJS.G.01512.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.